Research Update: NAD Levels Decline with Age. Do They Really?
Your NAD levels decline with age. Based on this hypothesis, NAD+, NMN and NR have been aggressively marketed as longevity “miracle molecules” in recent years. New human studies now challenge this assumption. What does that mean for the longevity debate?
In the longevity space, a clear narrative has dominated: NAD+ declines with age and is a central driver of biological aging. However, current human data do not provide clear evidence for a general age-related decline of NAD+ levels in human whole blood.
A recent New York Times article has reignited the discussion around NAD+, NMN and so-called NAD boosters. But what is actually behind this? And does this mean the NAD hypothesis is wrong?
Why NAD+ matters
NAD+ is a coenzyme found in nearly every cell. It plays a key role in energy production, DNA repair and metabolic processes.
This is why it has been considered one of the most promising targets in longevity research.
Many supplements such as NMN or nicotinamide riboside aim to increase NAD levels.
However, one point is critical: Just because NAD+ is biologically essential does not mean that artificially increasing its levels leads to clinical benefits in healthy individuals.
The underlying theory has never been as conclusively proven as often suggested.
New studies: stable NAD levels in blood
In May 2026, a study published in Nature Metabolism reported a key finding: NAD+ levels in whole blood do not appear to change systematically with age.
The analysis included multiple human cohorts with over 300 individuals, ranging from young adults to elderly and frail individuals, as well as athletes.
The result: NAD levels in whole blood remained surprisingly stable across age groups.
No consistent relationship was found between physical activity or lifestyle factors and NAD levels.
NAD boosters were able to increase blood levels. However, this only shows that a biomarker can be changed. It does not demonstrate a clinical benefit.
A second study shows similar results
An earlier preprint study from 2025 reported comparable findings.
Again, no clear age-related changes in NAD blood levels were observed in healthy adults.
Some differences were noted, such as slightly higher levels in men and potential effects from niacin.
Important: This study has not yet been peer-reviewed and should be interpreted cautiously.
What this means for the NAD hypothesis
These findings do not suggest that NAD+ is irrelevant.
They suggest that a general age-related decline in human whole-blood NAD levels cannot currently be clearly demonstrated.
A key limitation: blood levels are not the same as tissue levels.
NAD is regulated differently across organs. Muscle, brain and liver tissue may behave differently from what is measurable in blood.
Blood levels are therefore a marker, but not a complete representation of the system.
The broader issue in longevity narratives
In longevity research, early mechanistic hypotheses are often communicated as established facts.
This has led to simplified assumptions:
- NAD declines inevitably with age
- this decline drives aging
- NAD boosters can directly reverse this process
Current human data clearly challenge this simplified narrative.
This does not invalidate NAD research. It highlights its complexity.
Many positive effects of NAD boosters are still primarily based on cell, animal or disease models. Their relevance for healthy humans remains unclear.
Biomarker increase does not equal better health
An important point: Changing a biomarker does not automatically improve health.
It is well established that NAD boosters increase blood levels.
What remains unclear:
- whether this leads to real benefits in healthy individuals
- whether aging processes are affected
- whether clinical outcomes improve
This is why robust human studies and careful interpretation are essential.
Lack of human data on NAD precursors
It is often argued that the limited evidence is due to a lack of patentability, making large clinical studies less attractive.
This explanation is likely incomplete.
Another key reason is the heterogeneity of preclinical data, which is less consistent than often suggested in public narratives.
Within aging research, the clinical relevance of NAD precursors is now discussed more cautiously than in previous years.
Our perspective
NAD+ remains biologically relevant and an exciting research area.
However, current data show that the picture is more complex and less certain than many marketing narratives suggest.
The gap between plausible biological theory, strong animal data and proven clinical benefit in humans is often substantial.
A rising biomarker does not equal better health.
The new data do not invalidate NAD research, but they highlight the importance of careful interpretation.
Aging is complex. This is precisely why simple “miracle solutions” should be viewed critically, especially when robust human data are lacking.